Abbott Reissued FDA Emergency Use Authorization for ID Now COVID-19 Test
By HospiMedica International staff writers Posted on 21 Sep 2020 |
Image: Abbott ID Now (Photo courtesy of Abbott)
Abbott (Lake Forest, IL, USA) has been reissued Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the company's ID Now COVID-19 test.
The revisions to the previous EUA letter of authorization include a revised intended use to indicate that testing is for specimens collected “from individuals who are suspected of COVID-19 by their health care provider within the first seven days of the onset of symptoms;” clarify that testing is authorized for laboratories certified under CLIA and meet the requirements to perform high, moderate, or waived complexity tests; and clarify that testing facilities within the United States and its territories are required to report all results to the appropriate public health authorities.
The reissuance has also revised the labeling to update specimen transport and storage recommendations and to include results of the FDA SARS-CoV-2 Reference Panel Testing; updated conditions of authorization to reflect consistency with more recent authorizations; and revised the health care provider and patient fact sheets to reflect the intended use updates and language more consistent with recent authorizations.
The revisions to the previous EUA letter of authorization include a revised intended use to indicate that testing is for specimens collected “from individuals who are suspected of COVID-19 by their health care provider within the first seven days of the onset of symptoms;” clarify that testing is authorized for laboratories certified under CLIA and meet the requirements to perform high, moderate, or waived complexity tests; and clarify that testing facilities within the United States and its territories are required to report all results to the appropriate public health authorities.
The reissuance has also revised the labeling to update specimen transport and storage recommendations and to include results of the FDA SARS-CoV-2 Reference Panel Testing; updated conditions of authorization to reflect consistency with more recent authorizations; and revised the health care provider and patient fact sheets to reflect the intended use updates and language more consistent with recent authorizations.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans